AU2003221897A1 - Compositions and methods for the diagnosis and treatment of herpes simplex virus infection - Google Patents

Compositions and methods for the diagnosis and treatment of herpes simplex virus infection Download PDF

Info

Publication number
AU2003221897A1
AU2003221897A1 AU2003221897A AU2003221897A AU2003221897A1 AU 2003221897 A1 AU2003221897 A1 AU 2003221897A1 AU 2003221897 A AU2003221897 A AU 2003221897A AU 2003221897 A AU2003221897 A AU 2003221897A AU 2003221897 A1 AU2003221897 A1 AU 2003221897A1
Authority
AU
Australia
Prior art keywords
seq
hsv
polypeptide
sequence
sets forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003221897A
Other languages
English (en)
Inventor
Craig H. Day
Nancy A. Hosken
Joseph M. Parsons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/121,988 external-priority patent/US20030068327A1/en
Priority claimed from US10/200,562 external-priority patent/US20030165819A1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AU2003221897A1 publication Critical patent/AU2003221897A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/035—Herpes simplex virus I or II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2003221897A 2002-04-11 2003-04-09 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection Abandoned AU2003221897A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10/121,988 US20030068327A1 (en) 2000-06-29 2002-04-11 Compositions and methods for the diagnosis and threatment of herpes simplex virus infection
US10/121,988 2002-04-11
US10/200,562 US20030165819A1 (en) 2000-06-29 2002-07-19 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US10/200,562 2002-07-19
US10/237,551 2002-09-06
US10/237,551 US6821519B2 (en) 2000-06-29 2002-09-06 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
PCT/US2003/011231 WO2003086308A2 (en) 2002-04-11 2003-04-09 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection

Publications (1)

Publication Number Publication Date
AU2003221897A1 true AU2003221897A1 (en) 2003-10-27

Family

ID=29255203

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003221897A Abandoned AU2003221897A1 (en) 2002-04-11 2003-04-09 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection

Country Status (6)

Country Link
US (1) US6821519B2 (https=)
EP (1) EP1492563A4 (https=)
JP (1) JP2005522210A (https=)
AU (1) AU2003221897A1 (https=)
CA (1) CA2481087A1 (https=)
WO (1) WO2003086308A2 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375952B1 (en) * 1998-08-07 2002-04-23 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
US6507042B1 (en) * 1998-12-25 2003-01-14 Fujitsu Limited Semiconductor device and method of manufacturing the same
CA2418854A1 (en) * 2000-08-17 2002-02-21 Jorg Fritz A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
ATE488249T1 (de) * 2001-07-31 2010-12-15 Univ Washington Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung
DK1523582T3 (da) 2002-07-18 2009-03-02 Univ Washington Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
US7267940B2 (en) * 2003-03-04 2007-09-11 Bio-Rad Laboratories, Inc. HSV-2 type-specific immunoassays using glycoprotein G2 peptides
WO2004091491A2 (en) * 2003-04-10 2004-10-28 Transform Pharmaceuticals, Inc. Profiling conformational variants, antibody compositions and methods of using the same
EP1618214A4 (en) * 2003-04-25 2008-02-13 Becton Dickinson Co DETECTION OF TYPES 1 AND 2 OF HERPES SIMPLEX VIRUS BY AMPLIFICATION OF NUCLEIC ACID
CA2538794C (en) * 2003-09-12 2016-04-19 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US7638318B2 (en) * 2003-09-26 2009-12-29 Norvartis Ag Seneca Valley virus based compositions and methods for treating disease
AU2004318223B8 (en) * 2004-03-05 2009-09-17 Bio-Rad Laboratories, Inc. HSV-2 type-specific immunoassays using glycoprotein G2 peptides
US7943589B2 (en) * 2005-06-03 2011-05-17 President And Fellows Of Harvard College siRNA microbicides for preventing and treating diseases
US7763460B2 (en) * 2005-06-24 2010-07-27 Focus Diagnostics, Inc. Methods and compositions for detecting herpes simplex virus type 2
CA2658484A1 (en) * 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
WO2008030560A2 (en) 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsyvania Hsv-1 and hsv-2 vaccines and methods of use thereof
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
US9284355B2 (en) 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US20130028925A1 (en) * 2006-12-28 2013-01-31 Harvey Friedman Herpes simplex virus combined subunit vaccines and methods of use thereof
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
US9044447B2 (en) * 2009-04-03 2015-06-02 University Of Washington Antigenic peptide of HSV-2 and methods for using same
EP3756684A1 (en) 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP6055776B2 (ja) * 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
US9233153B2 (en) 2011-10-05 2016-01-12 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
JP6757120B2 (ja) 2011-10-05 2020-09-16 ジェンヴェック エルエルシー アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法
CN103987726B (zh) 2011-10-05 2017-10-03 金维克有限公司 猴(大猩猩)腺病毒或腺病毒载体及其使用方法
AU2012340712B2 (en) * 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
HRP20181102T1 (hr) * 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
HK1210475A1 (en) 2012-05-29 2016-04-22 Genvec, Inc. Herpes simplex virus vaccine
KR101962683B1 (ko) * 2016-09-28 2019-03-27 주식회사 에스엘백시젠 Hsv-2 감염 예방 및 치료용 dna 백신
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
WO2018186755A1 (en) * 2017-04-04 2018-10-11 Beagley Kenneth Novel vaccine for the prevention or treatment of an infection caused by a herpes virus.
CN109701008B (zh) * 2019-02-18 2022-06-21 山东兴瑞生物科技有限公司 针对单纯疱疹病毒的治疗性dc复合疫苗及其制备方法
WO2021015987A1 (en) * 2019-07-19 2021-01-28 Merck Sharp & Dohme Corp. Antigenic glycoprotein e polypeptides, compositions, and methods of use thereof
US20220273789A1 (en) * 2019-07-21 2022-09-01 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
WO2025153100A1 (en) * 2024-01-19 2025-07-24 Sichuan Clover Biopharmaceuticals, Inc. Herpes simplex virus recombinant antigen and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW232710B (https=) 1991-09-13 1994-10-21 American Cyanamid Co
US5776468A (en) * 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
WO1996032962A1 (en) * 1995-04-21 1996-10-24 The University Of New Mexico Immunoassay for herpes simplex virus
AT404838B (de) 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
CA2270282A1 (en) * 1996-11-04 1998-05-14 Smithkline Beecham Corporation Novel coding sequences from herpes simplex virus type-2
US6022847A (en) * 1997-03-19 2000-02-08 Zymogenetics, Inc. Secreted salivary zsig32 polypeptides
EP0984790A1 (en) 1997-06-02 2000-03-15 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
CA2330230A1 (en) 1998-06-10 1999-12-16 Smithkline Beecham Corporation Herpes simplex virus origin binding protein n-terminal truncation (obp-nt)
US6375952B1 (en) 1998-08-07 2002-04-23 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
EP1222281B1 (en) 1999-09-30 2006-11-15 University of Washington Immunoligically significant herpes simplex virus antigens

Also Published As

Publication number Publication date
US20030165820A1 (en) 2003-09-04
EP1492563A2 (en) 2005-01-05
CA2481087A1 (en) 2003-10-23
WO2003086308A3 (en) 2004-03-11
JP2005522210A (ja) 2005-07-28
WO2003086308A2 (en) 2003-10-23
US6821519B2 (en) 2004-11-23
EP1492563A4 (en) 2006-03-15

Similar Documents

Publication Publication Date Title
US6821519B2 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6630574B1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001040269A2 (en) Compositions and methods for therapy and diagnosis of breast cancer
CA2407352A1 (en) Compositions and methods for the therapy and diagnosis of acne vulgaris
WO2001079286A2 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU2001273128B2 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
AU2001273128A1 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6844325B2 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
US20050130132A1 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6667154B1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000078960A9 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001057207A2 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001070976A2 (en) Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
WO2001073031A2 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
EP1366157A2 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003020108A2 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6686447B1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
US6914132B1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002012332A2 (en) Compositions and methods for the therapy and diagnosis of colon cancer
US20020111308A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2001090154A2 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2006200910A1 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030008299A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
US20020137911A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2007201253A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application